REPOSITORY > RESULTS

Doctoral dissertation

Proteomic characterization of legumain and its physiological substrates

Author(s): Robert Vidmar (Author), Marko Fonović (Supervisor)

Thesis defense date: 20.12.2016

Organization: MPŠ - Mednarodna podiplomska šola Jožefa Stefana

PID: 20.500.12556/ReVIS-15018

Views: 2 | Downloads: 0

Abstract

Determination of (patho)physiological roles of proteases remains an important aspect to
understand the organism as a functioning whole of interconnected biochemical processes.
Based on the technological progress and advances in the field of systems biology, the term
protease web was introduced. The later has put the research of proteases into perspective
of complex rather than the reductionistic view on protease-substrate systems. Proteases
represent a crucial link in otherwise complex processes such as immune response,
catabolism, cell death and differentiation, among others. In order to understand the
protease function and determine their role, studies are performed on various levels such as
substrate and inhibitory kinetics, specificity determination, cleavage assay development
thus connecting therapy with discovery of the role of proteases in disease. Additionally,
the information about the number of proteases in human (more than 550 or > 2 % human
genome) provides an insight into their importance in the cell and the extent of research
needed to characterise and determine the role of each individual protease.
Our research was focused on the lysosomal cysteine asparagine endopeptidase, also
called legumain. Research of this rather recently identified protease gained importance after
it was observed to have a role in the immune response and cancer, in addition to its unique
asparagine cleavage specificity. In this doctoral dissertation, we performed in vitro and in
vivo studies of legumain. In the first part we were focused on in vitro characterization of
legumain specificity based on the developed methodology using label and label-free
approaches. In the second part we investigated the role of legumain in the cells. We
simulated the extracellular milieu of cancer cells and membrane protein release with an
addition of recombinant legumain on cells. Moreover, we also determined in vivo legumain
substrates in cancer cells with silenced legumain. Lastly, we performed a proteomic
investigation of macrophages and liver of legumain knock out mice.
The main results of this work are the development and implementation of two
methodologies for determination of protease specificity. One is the FPPS approach (4.1.1)
that enables profiling of protease specificity on native substrates using N-terminal labelling.
The second methodology is DIPPS (4.1.2) developed for label-free determination of
protease specificity on a set of denaturated and gel-separated proteins. We validated
DIPPS methodology using proteases with known specificity (trypsin, endoprotease GluC,
caspase-7, cathepsins B, K, L, S and V) and determined the first specificity profile of
legumain at different pH values. At optimal pH we confirmed canonical asparagine
specificity, whereas lowering the pH (from 6.0 to 4.0) was accompanied by a drastic
reduction of cleavage specificity. FPPS approach originally developed for the determination
of cleavage specificity of proteases with broad specificity (i.e. cysteine cathepsins) was also successfully applied for profiling narrow asparagine specificity of legumain.
Simulation of tumor microenvironment was carried out by performing shedding
experiments on breast cancer cells (MDA-MB-231) with recombinant legumain, thus
enabling the determination of several membrane targets. We identified EGFR, EPHA2,
PLXB2, MCSF as substrate membrane proteins shed by legumain. Additional validation
was performed using topographic representation of identified peptides (PROTOMAP) and
immunodetection of released fragments (4.2.1 and 4.2.2).
The proteomic analysis of HT-144 cancer cells with silenced legumain showed only minor
differences, that can be attributed to the silencing (4.2.3). However, despite minimal
changes we identified novel legumain substrates (GNS, MAN2B1), as well as confirmed
some of the previously known substrates (CTSL) by combining protein quantification using
stable isotope labelling of amino acids (SILAC) with evaluation of topographic differences
in cleaved substrate gel migration.
In addition, we also characterized Lgmn-/- knock out mouse model by proteomic analysis
and confirmed legumain substrate Gns previously detected in our cell experiments.
Moreover, we identified novel legumain substrates (Chil3, Mpo, Epx, Ggh) (4.2.4). The
proteomic comparison of bone marrow derived macrophages and liver suggests an
important role of legumain in lysosome homeostasis and potential role in lysosomal storage
diseases.

Attachments

Cite this work